- Home
- CYH vs EYPT Comparison
CYH vs EYPT Comparison
Compare CYH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- EYPT
- Stock Information
- Founded
- CYH 1985
- EYPT 1987
- Country
- CYH United States
- EYPT United States
- Employees
- CYH N/A
- EYPT N/A
- Industry
- CYH Hospital/Nursing Management
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CYH Health Care
- EYPT Industrials
- Exchange
- CYH Nasdaq
- EYPT Nasdaq
- Market Cap
- CYH 440.4M
- EYPT 489.4M
- IPO Year
- CYH 1991
- EYPT 2005
- Fundamental
- Price
- CYH $3.20
- EYPT $7.69
- Analyst Decision
- CYH Hold
- EYPT Strong Buy
- Analyst Count
- CYH 6
- EYPT 8
- Target Price
- CYH $4.40
- EYPT $25.71
- AVG Volume (30 Days)
- CYH 1.9M
- EYPT 665.0K
- Earning Date
- CYH 02-18-2025
- EYPT 03-06-2025
- Dividend Yield
- CYH N/A
- EYPT N/A
- EPS Growth
- CYH N/A
- EYPT N/A
- EPS
- CYH N/A
- EYPT N/A
- Revenue
- CYH $12,551,000,000.00
- EYPT $45,713,000.00
- Revenue This Year
- CYH $1.16
- EYPT N/A
- Revenue Next Year
- CYH $1.18
- EYPT N/A
- P/E Ratio
- CYH N/A
- EYPT N/A
- Revenue Growth
- CYH 0.81
- EYPT 7.50
- 52 Week Low
- CYH $2.51
- EYPT $6.90
- 52 Week High
- CYH $6.29
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- CYH 45.86
- EYPT 41.66
- Support Level
- CYH $3.20
- EYPT $7.58
- Resistance Level
- CYH $3.39
- EYPT $8.16
- Average True Range (ATR)
- CYH 0.16
- EYPT 0.55
- MACD
- CYH 0.02
- EYPT -0.07
- Stochastic Oscillator
- CYH 47.14
- EYPT 3.06
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.